RemeGen Co., Ltd. Annual Report 2025: Key Financial and Corporate Highlights

1. Robust Financial Performance and Turnaround

• Revenue Surge: RemeGen posted revenue of RMB 3.24 billion for 2025, up markedly from RMB 1.71 billion in 2024—a growth of approximately 90%. This reflects strong sales momentum, likely driven by commercial success of core products.
• Return to Profitability: The company achieved a net profit of RMB 709.7 million in 2025, compared to a net loss of RMB 1.47 billion in 2024. This turnaround is significant and could positively impact investor sentiment and share price.
• Earnings Per Share: Basic/diluted earnings per share were RMB 1.29, a sharp improvement from RMB (2.73) in 2024.
• Gross Margin: Gross profit rose to RMB 2.82 billion from RMB 1.37 billion, with cost of sales only increasing modestly, indicating improved operational efficiency.
• Other Income and Gains: Other income ballooned to RMB 691.8 million (from RMB 105.2 million), suggesting successful investment and financing activities.
• Research & Development: R&D expenses decreased from RMB 1.54 billion to RMB 1.22 billion, showing improved cost management while maintaining innovation.

2. Capital Management and Shareholder Structure Updates

• H Share Placement: On May 29, 2025, RemeGen placed 19,000,000 new H Shares at HK\$42.44 per share, raising HK\$796 million net (approx. RMB 731 million). This broadened the shareholder base and signaled confidence from institutional investors.
• Share Capital: Total issued shares increased to 563,710,243, reflecting new issuances and exercised share awards.
• Dividend Policy: No dividends have been declared or paid. The company intends to retain earnings for growth and expansion; future dividends are contingent on profitability, reserves, and regulatory compliance. Shareholders should note the priority of covering historical losses and allocating profits to statutory reserves before any dividend declaration.
• Share Schemes: Multiple share incentive plans (First and Second H Share Schemes, 2022 and 2023 A Share Schemes) are active, signaling emphasis on talent retention and aligning management interests with shareholders.

3. Corporate Governance and Risk Management

• Board Practices: Board meetings are held quarterly with strong governance protocols, including independent advice access and detailed minute keeping.
• Risk Management: Comprehensive risk framework includes oversight by Audit Committee and Board, regular risk reviews, and formal policies across finance, legal, and HR. Key risks disclosed include market competition, supply chain dependence, R&D uncertainty, and macroeconomic shifts.
• Internal Controls: Annual review confirmed effectiveness of risk management and internal control systems, with no material financial, operational, or compliance concerns raised.
• Shareholder Rights: Shareholders holding 10%+ can convene EGMs; those with 1%+ can submit resolutions. Multiple communication channels are maintained for transparency and investor engagement.

4. Principal Risks and Uncertainties

• Financial Risks: Working capital relies on sales and external financing. Any adverse shifts in core product sales, medical insurance policies, or R&D outcomes could impact profitability and liquidity.
• Industry Policy Risks: Policy environment is supportive but transitioning to maturity and competition. RemeGen’s inclusion of two products in the National Reimbursement Drug List is positive, but future regulatory or reimbursement changes may affect earnings.
• Supply Chain Risks: Dependence on foreign suppliers for key materials poses risks if international trade or logistics are disrupted.
• Operational Risks: Success hinges on clinical and pre-clinical drug candidates; delays or failures can materially harm business. Talent retention and legal proceedings also pose risks.

5. Environmental, Social, and Governance (ESG)

• ESG Initiatives: Robust EHS (Environmental, Health, Safety) policies are in place, with regular safety training and compliance monitoring. The company maintains strong stakeholder relationships and complies with all material laws and regulations.
• Donations: Charitable donations totaled RMB 12.51 million in 2025.

6. Material Transactions and Related Party Disclosures

• Connected Transactions: Auditor confirmed all continuing connected transactions were in the ordinary course of business, on fair terms, and within annual caps. No material related party transactions requiring disclosure under Listing Rules.
• Non-Competition Undertaking: Controlling Shareholders have confirmed compliance, and no Director or associate has an interest in competing businesses.

7. Financial Position and Outlook

• Assets and Equity: Total assets grew to RMB 7.25 billion, equity to RMB 3.61 billion, indicating strengthening financial health.
• Bank Loans: Details of borrowings and capital management are provided; the company is not subject to external capital requirements.
• Risk Sensitivities: The company disclosed sensitivity to interest rate and foreign exchange movements, providing transparency to investors on financial exposures.

8. Shareholder and Corporate Actions

• Constitutional Amendments: Articles of Association were amended to streamline governance, increase shareholder rights, and reflect new capital structure after share placement.
• Public Float: Maintained as required under Listing Rules.
• Shareholder Communication: Multiple channels for investor queries and regular updates via website, press releases, and investor conferences.

Potential Price-Sensitive Information

• The strong return to profitability and revenue growth may materially affect investor sentiment and share value.
• The successful H Share placement and broadened institutional investor base could signal confidence and potentially drive share price up.
• Risk disclosures around supply chain, policy changes, and R&D uncertainty are important for investors to monitor.
• Dividend policy remains conservative; shareholders should not expect dividends until historical losses are covered and statutory reserves are fulfilled.

Disclaimer

This article is for informational purposes only and does not constitute investment advice. Investors should review the full annual report and consult their own advisers before making any investment decisions. The author has made reasonable efforts to ensure accuracy but cannot guarantee completeness or timeliness. Share prices can be affected by multiple factors including, but not limited to, those discussed above.

View REMEGEN Historical chart here